Brokerages Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $154.08

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has received an average rating of “Moderate Buy” from the twenty-three brokerages that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $154.08.

NBIX has been the topic of several recent analyst reports. Wells Fargo & Company raised shares of Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $140.00 to $170.00 in a research report on Wednesday, April 24th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Thursday. Wedbush reiterated an “outperform” rating and issued a $152.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, May 29th. Oppenheimer lifted their price target on shares of Neurocrine Biosciences from $200.00 to $216.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. Finally, BMO Capital Markets lifted their price target on shares of Neurocrine Biosciences from $129.00 to $138.00 and gave the stock a “market perform” rating in a research note on Thursday, May 2nd.

Insider Transactions at Neurocrine Biosciences

In other news, insider Julie Cooke sold 900 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $150.04, for a total value of $135,036.00. Following the transaction, the insider now owns 18,202 shares of the company’s stock, valued at $2,731,028.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Ingrid Delaet sold 273 shares of the company’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $140.55, for a total transaction of $38,370.15. Following the sale, the insider now owns 7,507 shares of the company’s stock, valued at $1,055,108.85. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Julie Cooke sold 900 shares of the company’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $150.04, for a total transaction of $135,036.00. Following the sale, the insider now directly owns 18,202 shares in the company, valued at approximately $2,731,028.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 80,709 shares of company stock valued at $11,009,150. 4.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds have recently bought and sold shares of the business. RFP Financial Group LLC raised its stake in Neurocrine Biosciences by 346.5% during the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after purchasing an additional 149 shares in the last quarter. Mather Group LLC. purchased a new stake in Neurocrine Biosciences during the first quarter valued at $26,000. Lindbrook Capital LLC raised its stake in Neurocrine Biosciences by 85.0% during the fourth quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after purchasing an additional 96 shares in the last quarter. EdgeRock Capital LLC bought a new position in Neurocrine Biosciences during the fourth quarter valued at $31,000. Finally, New Covenant Trust Company N.A. bought a new position in Neurocrine Biosciences during the first quarter valued at $32,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $146.80 on Wednesday. Neurocrine Biosciences has a one year low of $99.36 and a one year high of $150.39. The company’s 50-day moving average is $139.16 and its 200 day moving average is $137.97. The company has a market capitalization of $14.77 billion, a price-to-earnings ratio of 40.44 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $1.04 by ($0.62). Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. The firm had revenue of $515.30 million for the quarter, compared to analysts’ expectations of $512.21 million. As a group, research analysts predict that Neurocrine Biosciences will post 4.22 earnings per share for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.